ÂÜÀòÂÒÂ×

Eric Meldrum has 12 years of drug discovery experience at GSK in Switzerland and the UK. Until 2005 he was head of the Asthma and Rhinitis Disease Biology Department responsible for drug development up to Phase 2 proof of concept. Since then, Eric has been active as CSO in several biotech companies and brings Citryll a depth of experience in translational approaches to prioritise therapeutic opportunities and the strategic considerations behind successfully enhancing asset value and progression to clinical proof of concept. He was most recently CSO at ENYO Pharma, a French biotech currently in Phase 2 in Chronic Hepatitis B and NASH. Eric is responsible for the overall preclinical and clinical scientific and therapeutic strategy and to develop partnerships with pharma.